Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics

P-glycoprotein (also known as multidrug resistance protein 1 (MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) plays a crucial role in determining response against medications, including cancer therapeutics. It is now well established that p-glycoprotein acts as an ATP dependent pump that...

Full description

Bibliographic Details
Main Authors: Jiun-I Lai, Yu-Jhen Tseng, Ming-Huang Chen, Chi-Ying F. Huang, Peter Mu-Hsin Chang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
p-glycoprotein
repurposing
cancer
drug resistance
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.561936/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.561936/full

Similar Items